ProSensa Holding N.V. Comments On Drisapersen Program Update

Published: Dec 20, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Leiden, The Netherlands, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, commented on a recent update by GlaxoSmithKline (GSK) to patient groups and investigators regarding the ongoing analyses for drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, which is exclusively licensed to GSK.

Help employers find you! Check out all the jobs and post your resume.

Back to news